Bringing the ALS Patient Perspective to Canada’s Drug Policy Reform Debate
ALS Action Canada Member Dr. Andrew Darke, who is living with ALS, is contributing to the national debate on drug policy reform. In a Financial Post commentary with Nigel Rawson and John Adams, he examines how recent U.S. trade policies strengthen the case for reforms to Canada’s drug approval, pricing and coverage processes. For ALS Action Canada, advocating for timely and equitable access to innovative treatments remains a key priority.